Stephen F Butler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5330730/publications.pdf

Version: 2024-02-01

108 papers	6,042 citations	36 h-index	7	76 g-index
111 all docs	111 docs citations	111 times ranked		3531 citing authors

#	Article	IF	CITATIONS
1	Development and validation of the Current Opioid Misuse Measure. Pain, 2007, 130, 144-156.	4.2	545
2	Psychosocial Treatments for Cocaine Dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Archives of General Psychiatry, 1999, 56, 493-502.	12.3	472
3	Validation of the Revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R). Journal of Pain, 2008, 9, 360-372.	1.4	402
4	Validation of a screener and opioid assessment measure for patients with chronic pain. Pain, 2004, 112, 65-75.	4.2	308
5	Effects of training in time-limited dynamic psychotherapy: Changes in therapist behavior Journal of Consulting and Clinical Psychology, 1993, 61, 434-440.	2.0	299
6	Psychiatric History and Psychologic Adjustment as Risk Factors for Aberrant Drug-related Behavior Among Patients With Chronic Pain. Clinical Journal of Pain, 2007, 23, 307-315.	1.9	204
7	Case reports and hypothesis: A neglect-like syndrome may be responsible for the motor disturbance in reflex sympathetic dystrophy (complex regional pain syndrome-1). Journal of Pain and Symptom Management, 1995, 10, 385-391.	1.2	182
8	Validation and Clinical Application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). Journal of Pain and Symptom Management, 2006, 32, 287-293.	1.2	172
9	Cross Validation of the Current Opioid Misuse Measure to Monitor Chronic Pain Patients on Opioid Therapy. Clinical Journal of Pain, 2010, 26, 770-776.	1.9	167
10	Effects of training in time-limited dynamic psychotherapy: Mediators of therapists' responses to training Journal of Consulting and Clinical Psychology, 1993, 61, 441-447.	2.0	166
11	Abuse Rates and Routes of Administration of Reformulated Extended-Release Oxycodone: Initial Findings From a Sentinel Surveillance Sample of Individuals Assessed for Substance Abuse Treatment. Journal of Pain, 2013, 14, 351-358.	1.4	166
12	Specific and nonspecific factors in psychotherapy: A problematic paradigm for psychotherapy research Psychotherapy, 1986, 23, 30-40.	1.2	159
13	Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduction Journal, 2011, 8, 29.	3.2	148
14	Effects of training in time-limited dynamic psychotherapy: Changes in therapist behavior Journal of Consulting and Clinical Psychology, 1993, 61, 434-440.	2.0	132
15	Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). Journal of Addiction Medicine, 2009, 3, 66-73.	2.6	126
16	Women who abuse prescription opioids: Findings from the Addiction Severity Index-Multimedia Version® Connect prescription opioid database. Drug and Alcohol Dependence, 2009, 103, 65-73.	3.2	123
17	Identifying prescription opioid use disorder in primary care: Diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain, 2011, 152, 397-402.	4.2	118
18	Individual Differences in Memory for Dreams: The Role of Cognitive Skills. Perceptual and Motor Skills, 1985, 61, 823-828.	1.3	114

#	Article	IF	CITATIONS
19	Gender Differences in Risk Factors for Aberrant Prescription Opioid Use. Journal of Pain, 2010, 11, 312-320.	1.4	108
20	Does Report of Craving Opioid Medication Predict Aberrant Drug Behavior Among Chronic Pain Patients?. Clinical Journal of Pain, 2009, 25, 193-198.	1.9	100
21	Six-Month Treatment Outcomes of Cocaine-Dependent Patients With and Without PTSD in a Multisite National Trial. Journal of Studies on Alcohol and Drugs, 2007, 68, 353-361.	1.0	97
22	National addictions vigilance intervention and prevention program (NAVIPPROâ"¢): a realâ€time, productâ€specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiology and Drug Safety, 2008, 17, 1142-1154.	1.9	94
23	Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation. Pain Medicine, 2014, 15, 440-451.	1.9	79
24	Effects of training in time-limited dynamic psychotherapy: Mediators of therapists' responses to training Journal of Consulting and Clinical Psychology, 1993, 61, 441-447.	2.0	72
25	Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiology and Drug Safety, 2010, 19, 627-637.	1.9	69
26	Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment. Pain Medicine, 2015, 16, 119-130.	1.9	66
27	Training in psychodynamic therapy Journal of Consulting and Clinical Psychology, 1988, 56, 689-695.	2.0	62
28	Internet-based Survey of Nonmedical Prescription Opioid Use in the United States. Clinical Journal of Pain, 2008, 24, 528-535.	1.9	62
29	Typologies of Prescription Opioid Use in a Large Sample of Adults Assessed for Substance Abuse Treatment. PLoS ONE, 2011, 6, e27244.	2.5	62
30	Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduction Journal, 2009, 6, 8.	3.2	56
31	Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49. Journal of Attention Disorders, 2015, 19, 630-640.	2.6	54
32	Affective Comorbidity in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Annals of Clinical Psychiatry, 1995, 7, 51-55.	0.6	50
33	Measuring Attractiveness for Abuse of Prescription Opioids. Pain Medicine, 2010, 11, 67-80.	1.9	47
34	Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduction Journal, 2006, 3, 5.	3.2	45
35	Food, mood, and attitude: Reducing risk for eating disorders in college women Health Psychology, 2005, 24, 567-578.	1.6	44
36	Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: A pilot case-control study Experimental and Clinical Psychopharmacology, 2008, 16, 429-434.	1.8	42

3

#	Article	IF	CITATIONS
37	The reliability and validity of a measure of self-understanding of interpersonal patterns Journal of Counseling Psychology, 1999, 46, 472-482.	2.0	39
38	Internet Surveillance: Content Analysis and Monitoring of Product-specific Internet Prescription Opioid Abuse-related Postings. Clinical Journal of Pain, 2007, 23, 619-628.	1.9	37
39	Measuring online endorsement of prescription opioids abuse: an integrative methodology. Pharmacoepidemiology and Drug Safety, 2012, 21, 1081-1092.	1.9	30
40	Nonmedical Use of Prescription ADHD Stimulant Medications Among Adults in a Substance Abuse Treatment Population. Journal of Attention Disorders, 2015, 19, 275-283.	2.6	29
41	Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse. Journal of Medical Internet Research, 2014, 16, e119.	4.3	29
42	The Effect of Computer-Mediated Administration on Self-Disclosure of Problems on the Addiction Severity Index. Journal of Addiction Medicine, 2009, 3, 194-203.	2.6	28
43	Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse. Pain Medicine, 2015, 16, 131-140.	1.9	28
44	Affective Comorbidity in Psychiatrically Hospitalized Adolescents with Conduct Disorder or Oppositional Defiant Disorder: Should Conduct Disorder Be Treated with Mood Stabilizers?. Journal of Child and Adolescent Psychopharmacology, 1994, 4, 151-158.	1.3	27
45	Characteristics of prescription opioid abusers in treatment: Prescription opioid use history, age, use patterns, and functional severity. Journal of Opioid Management, 2010, 6, 239-252.	0.5	27
46	Development and Preliminary Experience with an Ease of Extractability Rating System for Prescription Opioids. Drug Development and Industrial Pharmacy, 2006, 32, 727-746.	2.0	25
47	Feasibility of Tablet Computer Screening for Opioid Abuse in the Emergency Department. Western Journal of Emergency Medicine, 2015, 16, 18-23.	1.1	24
48	Measuring adherence in time-limited dynamic psychotherapy Psychotherapy, 1995, 32, 629-638.	1.2	23
49	Estimating Attractiveness for Abuse of a Not-Yet-Marketed "Abuse-Deterrent―Prescription Opioid Formulation. Pain Medicine, 2010, 11, 81-91.	1.9	23
50	A comparison of an opioid abuse screening tool and prescription drug monitoring data in the emergency department. Drug and Alcohol Dependence, 2016, 159, 152-157.	3.2	22
51	Development of a Brief Version of the Current Opioid Misuse Measure (COMM): The COMM-9. Pain Medicine, 2019, 20, 113-118.	1.9	22
52	Associations between public health indicators and injecting prescription opioids by prescription opioid abusers in substance abuse treatment. Journal of Opioid Management, 2013, 9, 5-17.	0.5	22
53	Predicting Addiction Severity Index (ASI) interviewer severity ratings for a computer-administered ASI Psychological Assessment, 1998, 10, 399-407.	1.5	21
54	Validation of the Spanish Addiction Severity Index Multimedia Version (S-ASI-MV). Drug and Alcohol Dependence, 2009, 99, 18-27.	3.2	19

#	Article	IF	Citations
55	CHAT: Development and Validation of a Computer-Delivered, Self-Report, Substance Use Assessment for Adolescents. Substance Use and Misuse, 2011, 46, 781-794.	1.4	19
56	Cross-validation of short forms of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R). Drug and Alcohol Dependence, 2017, 178, 94-100.	3.2	19
57	Computer-Assisted Screening and Intervention for Alcohol Problems in Primary Care. Journal of Technology in Human Services, 2003, 21, 1-19.	1.6	18
58	Neglect-like signs and symptoms in CRPS. Pain, 2013, 154, 961-962.	4.2	16
59	Shortening the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R): A Proof-of-Principle Study for Customized Computer-Based Testing. Pain Medicine, 2015, 16, 2344-2356.	1.9	15
60	Addiction severity assessment tool: Development of a self-report measure for clients in substance abuse treatment. Drug and Alcohol Dependence, 2005, 80, 349-360.	3.2	14
61	Shortening the Current Opioid Misuse Measure via computer-based testing: a retrospective proof-of-concept study. BMC Medical Research Methodology, 2013, 13, 126.	3.1	13
62	Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers. Journal of Substance Abuse Treatment, 2018, 84, 42-49.	2.8	13
63	Development and Validation of an Eight-Item Brief Form of the SOAPP-R (SOAPP-8). Pain Medicine, 2018, 19, 1982-1987.	1.9	13
64	Development of Short-Form Versions of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R): A Proof-of-Principle Study. Pain Medicine, 2016, 18, pnw210.	1.9	11
65	Spanish Translation and Linguistic Validation of the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R). Pain Medicine, 2013, 14, 1032-1038.	1.9	10
66	Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration. Pain Medicine, 2018, 19, 1613-1627.	1.9	10
67	Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index–Multimedia Version (ASI-MV). Pain Medicine, 2020, 21, 1891-1901.	1.9	10
68	Personality Disorder Styles and Reciprocal Interpersonal Impacts During Outpatient Intake Interviews. Psychotherapy Research, 1999, 9, 216-231.	1.8	9
69	Non-medical Use of Prescription Stimulants Among College Students: Non-oral Routes of Administration, Risk Factors, Motivations, and Pathways. Frontiers in Psychiatry, 2021, 12, 667118.	2.6	9
70	Development and Validation of the Post-Operative Recovery Index for Measuring Quality of Recovery after Surgery. Journal of Anesthesia & Clinical Research, 2012, 03, .	0.1	9
71	Working It Out: Development and Testing of a Multimedia, Vocational Education Program. Substance Use and Misuse, 2004, 39, 2525-2558.	1.4	8
72	Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product. Clinical Journal of Pain, 2018, 34, 618-628.	1.9	8

#	Article	IF	Citations
73	Prevalence of nonmedical use and routes of administration for prescription stimulant medications among adults in a substance abuse treatment population. Journal of Addictive Diseases, 2018, 37, 34-45.	1.3	8
74	Prescription Stimulant Nonmedical Use Among Adolescents Evaluated for Substance Use Disorder Treatment (CHATâ,,¢). Journal of Attention Disorders, 2021, 25, 1859-1870.	2.6	8
75	Electronic Opioid Risk Assessment Program for Chronic Pain Patients: Barriers and Benefits of Implementation. Pain Practice, 2014, 14, E98-E105.	1.9	7
76	An investigation of completion times on the Screener and Opioid Assessment for Patients with Pain & Eamp; ndash; revised (SOAPP-R). Journal of Pain Research, 2016, Volume 9, 1163-1171.	2.0	7
77	The bath water or the baby?. Addiction, 2004, 99, 413-414.	3.3	6
78	Illustration of a Statistical Process Control Approach to Regional Prescription Opioid Abuse Surveillance. Journal of Addiction Medicine, 2011, 5, 99-109.	2.6	6
79	Impact of an Electronic Pain and Opioid Risk Assessment Program: Are There Improvements in Patient Encounters and Clinic Notes?. Pain Medicine, 2016, 17, 2047-2060.	1.9	6
80	Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index—Multimedia Version (ASI-MV®) Network. Drug Safety, 2021, 44, 235-244.	3.2	6
81	Insight into chronic pain in the United States: descriptive results from the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) validation study. Current Medical Research and Opinion, 2021, 37, 483-492.	1.9	6
82	The effects of thematic context and presentation mode on memory for sentence voice. Journal of Psycholinguistic Research, 1982, 11, 247-264.	1.3	5
83	Cyclical Psychodynamics and the Triangle of Insight. Psychiatry (New York), 1987, 50, 218-231.	0.7	5
84	Assessment of Axis Ii Personality Disorders among Female Substance Abusers. Psychological Reports, 1991, 68, 1344-1346.	1.7	5
85	Construct validity and reproducibility of the Prescription Opioid Misuse And Abuse Questionnaire (POMAQ). Current Medical Research and Opinion, 2021, 37, 493-503.	1.9	5
86	How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users. JMIR Public Health and Surveillance, 2020, 6, e16038.	2.6	5
87	Establishing the content validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) among chronic pain patients. Current Medical Research and Opinion, 2021, 37, 505-514.	1.9	4
88	A computer adaptive testing version of the Addiction Severity Index—Multimedia Version (ASI–MV): The Addiction Severity CAT Psychology of Addictive Behaviors, 2017, 31, 265-275.	2.1	4
89	Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder. Journal of Opioid Management, 2017, 13, 425-440.	0.5	4
90	The assessment of outcome and value of psychiatric hospital treatment. New Directions for Mental Health Services, 1994, 1994, 83-94.	0.4	3

#	Article	IF	CITATIONS
91	A comprehensive system for value accounting in psychiatry. Journal of Mental Health Administration, 1996, 23, 479-491.	1.1	3
92	Corrigendum to "Development and validation of the current opioid misuse measure―[Pain 130 (2007) 144–56]. Pain, 2009, 142, 169.	4.2	3
93	Psychometric evaluation of the PainCAS Interference with Daily Activities, Psychological/Emotional Distress, and Pain scales. Quality of Life Research, 2018, 27, 835-843.	3.1	3
94	Burden of Schizophrenia or Psychosis-Related Symptoms in Adults Undergoing Substance Abuse Evaluation. Journal of Nervous and Mental Disease, 2018, 206, 528-536.	1.0	3
95	Computerâ€based testing and the 12â€item Screener and Opioid Assessment for Patients with Painâ€Revised: A combined approach to improving efficiency. Journal of Applied Biobehavioral Research, 2019, 24, e12145.	2.0	3
96	Psychotherapy versus placebo: Revisiting a pseudo issue. Behavioral and Brain Sciences, 1984, 7, 756-757.	0.7	2
97	Using the GLIMMIX Procedure in SAS 9.3 to Fit a Standard Dichotomous Rasch and Hierarchical 1-PL IRT Model. Applied Psychological Measurement, 2012, 36, 237-248.	1.0	2
98	Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®). Journal of Pain Research, 2021, Volume 14, 1773-1783.	2.0	2
99	Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study. JMIR Formative Research, 2022, 6, e16996.	1.4	2
100	Individual Differences in the Rorschach <i>M</i> Response and the Distribution of Phasic Integrated Potentials (PIPs) During Sleep. Perceptual and Motor Skills, 1983, 57, 507-514.	1.3	1
101	THE ADDICTION SEVERITY INDEX MULTIMEDIA VERSION. , 2008, , 141-159.		1
102	Reply to Commentary. Journal of Pain, 2013, 14, 361-362.	1.4	1
103	Response to Villarreal and Markman. Pain Medicine, 2014, 15, 877.1-877.	1.9	1
104	How did you know you got the right pill? Prescription opioid identification and measurement error in the abuse deterrent formulation era. Addiction Science & Elinical Practice, 2015, 10, .	2.6	1
105	Clinical scoring algorithm for the prescription opioid misuse and abuse questionnaire (POMAQ). Current Medical Research and Opinion, 2022, 38, 971-980.	1.9	1
106	Psychodynamic Psychotherapy. , 1995, , 213-229.		0
107	A Comparison of Short Forms of the Screener and Opioid Assessment for Patients With Pain – Revised (SOAPP-R). European Journal of Psychological Assessment, 2020, 36, 387-398.	3.0	O
108	Brief, Dynamic Psychotherapy: Briefly. PsycCritiques, 1983, 28, 880-880.	0.0	0